|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | University of Zurich |
|---|---|
| Collaborator: |
Sanofi-Aventis |
| Information provided by: | University of Zurich |
| ClinicalTrials.gov Identifier: | NCT00273533 |
Purpose
The present study is designed to evaluate the hypothesis that the Angiotensin‐Converting Enzyme (ACE) inhibitor Ramipril improves vascular function and reduces markers of low-grade chronic inflammation and oxidative stress in patients with Rheumatoid Arthritis.
| Condition | Intervention | Phase |
|---|---|---|
|
Arthritis, Rheumatoid |
Drug: Ramipril |
Phase II Phase III |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Crossover Assignment, Efficacy Study |
| Official Title: | Effects of Ramipril on Endothelial Function in Patients With Rheumatoid Arthritis |
| Enrollment: | 13 |
| Study Start Date: | June 2004 |
| Estimated Study Completion Date: | July 2006 |
The effect of an 8-week treatment with either ramipril or placebo is studied using a randomized, double-blind, and crossover protocol. After given written informed consent, baseline characteristics including physical examination, ECG, blood sample and a noninvasive assessment of endothelial function are obtained. The patients are randomly assigned to receive either ramipril 10mg (up-titration-scheme: starting with 2.5mg in Week1, then 5mg in Week2 followed by 2-5mg for the final 6 weeks) followed by placebo or vice versa.The individual disease-modifying antirheumatic drug therapy is continued throughout the study. The examinations are repeated after 8 weeks treatment of the first and 8 weeks after the second study drug. At week 1 and 2 in each treatment period a safety visit is scheduled.
Eligibility| Ages Eligible for Study: | 18 Years to 60 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations
More Information
| Study ID Numbers: | HOE498/6007 |
| Study First Received: | January 6, 2006 |
| Last Updated: | July 21, 2008 |
| ClinicalTrials.gov Identifier: | NCT00273533 History of Changes |
| Health Authority: | Switzerland: Swissmedic |
|
Autoimmune Diseases Immune System Diseases Molecular Mechanisms of Pharmacological Action Joint Diseases Arthritis, Rheumatoid Enzyme Inhibitors Cardiovascular Agents Rheumatic Diseases Antihypertensive Agents |
Pharmacologic Actions Ramipril Protease Inhibitors Musculoskeletal Diseases Therapeutic Uses Arthritis Connective Tissue Diseases Angiotensin-Converting Enzyme Inhibitors |